- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Optic radiation.
Displaying page 1 of 1.
EudraCT Number: 2017-001982-26 | Sponsor Protocol Number: OZM-063 | Start Date*: 2018-04-26 | |||||||||||
Sponsor Name:The Hospital for Sick Children | |||||||||||||
Full Title: A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma... | |||||||||||||
Medical condition: Unresectable or progressive low grade glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000690-23 | Sponsor Protocol Number: ADVL0612;NCI-07-C-0220 | Start Date*: 2012-02-29 | |||||||||||
Sponsor Name:National Institution of Health (NCI) | |||||||||||||
Full Title: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors | |||||||||||||
Medical condition: Paediatric solid tumours | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003275-34 | Sponsor Protocol Number: UHFRT | Start Date*: 2021-11-08 | |||||||||||
Sponsor Name:IRCCS-A.O.U. SAN MARTINO-IST | |||||||||||||
Full Title: TEMOZOLOMIDE + ULTRA-HYPER-FRACTIONATED RADIOTHERAPY VS TEMOZOLOMIDE ALONE FOR THE MAINTENANCE TREATMENT OF GLIOBLASTOMA PATIENTS - PILOT STUDY | |||||||||||||
Medical condition: histologically confirmed glioblastoma according to WHO criteria (grade IV). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001306-20 | Sponsor Protocol Number: ADVL0815 | Start Date*: 2012-03-08 | |||||||||||
Sponsor Name:The National Cancer Institute (NCI) | |||||||||||||
Full Title: A PHASE I STUDY OF PAZOPANIB AS A SINGLE AGENT FOR CHILDREN WITH RELAPSED OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS | |||||||||||||
Medical condition: Refractory solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003736-77 | Sponsor Protocol Number: E7080-A001-216 | Start Date*: 2023-03-28 |
Sponsor Name:Eisai Inc. | ||
Full Title: A Phase 1/2 Study of Lenvatinib in Combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors | ||
Medical condition: Recurrent and Refractory Solid Tumors | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-003005-10 | Sponsor Protocol Number: IGR2012/1883 | Start Date*: 2013-06-06 | |||||||||||||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||||||||||||
Full Title: PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA | |||||||||||||||||||||||
Medical condition: Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade g... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) FR (Ongoing) NL (Completed) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000371-42 | Sponsor Protocol Number: 3066K1-139-US | Start Date*: 2007-09-20 | |||||||||||||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaeuticals Inc. | |||||||||||||||||||||||
Full Title: A Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors | |||||||||||||||||||||||
Medical condition: Relapsed/refractory neuroblastoma,high-grade glioma, and rhabdomyosarcoma. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) DE (Completed) PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
